Skip to content

    IGCL

    IGCL
    Chemicals·14 Aug 2025
    Management Summary

    Indogulf Cropsciences Limited reported a strong Q1 FY26, with revenue growing 43.3% YoY to INR 189.4 crores and PAT surging 187.4% to INR 3.9 crores. This growth was primarily driven by domestic B2B and B2C segments, alongside robust performance in biologicals and plant nutrition. Despite a slight gross margin compression due to product mix, management expressed confidence in margin recovery and continued growth, supported by strategic capex, new product launches, and an improving working capital cycle.

    Highlights

    5

    • Revenue of INR 189.4 crores, up 43.3% YoY, driven by strong demand in core geographies and disciplined execution.

    • EBITDA grew 66.7% YoY to INR 9.9 crores, supported by operating leverage and cost optimization.

    • PAT increased 187.4% YoY to INR 3.9 crores, reflecting significant profit scaling.

    • Working capital days improved from 225 to 200 days, indicating better operational efficiency.

    • Biologicals segment grew 24.1% YoY, and plant nutrition grew 9.5% YoY, reinforcing focus on sustainable agri-inputs.

    Concerns

    2

    • Gross profit margin declined to 22% in Q1 FY26 from 24.6% in Q1 FY25, attributed to a higher proportion of lower-margin B2B sales.

    • Price corrections of 4-5% quarter-over-quarter on average, with some products seeing 8-15% drops.

    What Changed1

    vs Q2 FY26

    Guidance items7 → 11 (+4)

    Key financials

    Single quarter

    06 metrics
    1. 01Revenue₹189.4 Cr+43.3%YoY
    2. 02Gross Profit₹41.7 Cr+28.3%YoY
    3. 03EBITDA₹9.9 Cr+66.7%YoY
    4. 04PBT (before exceptional)₹4.6 Cr+5.1%YoY
    5. 05PAT₹3.9 Cr+1.9%YoY

    Segment breakdown

    Domestic B2B
    73.4% Growth
    Domestic B2C
    17% Growth
    Crop Protection
    90% Revenue Contribution— Growth
    Biologicals
    24.1% Growth
    Plant Nutrition
    9.5% Growth
    AGPL (AbhiPrakash Globus)
    6% Revenue Contribution— Growth
    List

    Capital allocation

    3
    high confidence
    CategoryHeadline
    Capex

    Capex disclosed

    Partially funded by IPO proceeds, own reserve and surplus, and bank loan (for existing CWIP)

    Debt

    Debt disclosed

    Liquidity

    Liquidity disclosed

    Working capital situation improved from 225 days to 200 days.

    Guidance & targets

    11
    CategoryTargetPriority
    Revenue Growth
    Biologicals and Nutrients Segment Growth
    30% to 40% increase
    		High
    Revenue Growth
    Overall Q2 FY26 Growth
    more than 20% to 25%
    		High
    Revenue Growth
    Annual YoY Growth
    30% to 35%
    		High
    Revenue
    Q2 FY26 Biologicals and Nutrients Sales
    around INR 300 crores
    		High
    Revenue
    Q2 FY26 B2C Topline
    approximately INR 180 crores to INR 200 crores
    		High
    Revenue
    Giraffe Mascot New Venture Revenue
    around INR 70 crores to INR 80 crores
    		High
    Margin
    Q2 FY26 Gross Margins
    higher
    		High
    Margin
    FY26 EBITDA Margins
    improving / better
    		High
    Capacity Expansion
    Overall Capacity Expansion
    almost 50% to 60%
    		High
    Capacity
    New Dry Flowable Plant Operationalization
    operational
    		High
    Capacity
    Peak Sales from Expanded Capacity
    INR 1,700 crores to INR 2,000 crores
    		Medium

    Q2 FY26 Biologicals and Nutrients Growth

    next quarter (Q2 FY26)
    CurrentQ1 FY26 growth of 24.1% YoY
    Target30-40% increase, ~INR 300 crores sales

    Why it matters

    This high-margin segment is a core focus area and is expected to significantly boost Q2 performance.

    We are expecting around 30% to 40% increase in the total numbers, the total growth of biologicals and nutrients. And overall, our Q2 results will demonstrate this performance.

    How to verify

    key_financials.segment_breakdown[name='Biologicals'].metrics[label='Growth']

    Risks & concerns

    3
    RiskSeverity

    Climatic changes and regulatory frameworks

    Climatic changes increase crop stress, necessitating resilient solutions. Tighter regulatory frameworks present both challenges and opportunities for R&D and compliance. — Management acknowledged

    medium

    Competition from China and weather-related demand fluctuations

    India faces competition from China and weather-related demand fluctuations in foreign markets as the second largest global agrochemical exporter. — Management acknowledged

    medium

    Price corrections in the market

    Some products saw 8-15% price corrections, but overall prices remained stable in Q1 with an average 4-5% QoQ correction. — Management acknowledged

    low

    Q&A highlights

    7

    “No, the prices are more or less stable. The price corrections are there. And the prices, there has not been any major ups and downs. And broadly, we have focused more on the high value and high cost products. So, broadly, the value-wise growth is there. And the prices remain almost stable in Q1. ... Volume growth is there. But as I mentioned that we worked on high-priced molecules in Q1. So, a slight lower maybe because it's a big basket. So, we cannot quantify exactly the volumes. But broadly, you can say that the growth is there approximately between 35% to 40% since we have worked on high-priced molecules.”

    Clarified that Q1 growth was primarily value-driven due to focus on high-priced molecules, with overall volume growth estimated at 35-40%.

    asked by Pratik Tholiya

    2 min read5 chapters

    Detailed Narrative

    01

    Robust Q1 FY26 Financial Performance

    Indogulf Cropsciences Limited commenced FY26 with a strong financial performance, reporting a 43.3% year-on-year increase in revenue from operations, reaching INR 189.4 crores. This growth was primarily fueled by a 73.4% surge in the domestic B2B segment and a 17.0% rise in the domestic B2C segment. EBITDA saw a significant 66.7% growth to INR 9.9 crores, while Profit After Tax (PAT) scaled 187.4% year-on-year to INR 3.9 crores, demonstrating strong operational leverage and cost optimization.

    02

    Margin Dynamics and Product Mix Strategy

    Despite the strong top-line growth, gross profit margin for Q1 FY26 stood at 22%, a decrease from 24.6% in Q1 FY25. Management attributed this to a higher proportion of lower-margin B2B sales in the first quarter. However, they anticipate a recovery in Q2, which is typically dominated by higher-margin B2C sales (28-33% gross margin) and high-value biologicals and plant nutrition products (65-95% gross margin). The company's focus on high-priced molecules contributed to value-wise growth in Q1, with overall volume growth estimated at 35-40%.

    03

    Strategic Capex and Capacity Expansion

    The company is actively pursuing capacity expansion, with INR 63 crores already invested in existing infrastructure and a fifth manufacturing unit, for which INR 35 crores from IPO proceeds were used to repay bank loans. An additional INR 14 crores is being invested in a new dry flowable plant in Sonipat, Haryana, expected to be commissioned by the end of the current fiscal year. This total capex of INR 77 crores is projected to have a payback period of 4-5 years at the EBITDA level and will enable the company to achieve peak sales of INR 1,700-2,000 crores from its five units.

    04

    Growth Drivers and Future Outlook

    Management provided an optimistic outlook, targeting an annual year-on-year growth of 30-35% for FY26, FY27, and FY28. Q2 FY26 is expected to see over 20-25% growth, with B2C topline projected at INR 180-200 crores and biologicals/nutrients sales around INR 300 crores. The new subsidiary, AbhiPrakash Globus, is expected to contribute INR 70-80 crores in FY26. The company's R&D pipeline includes multiple formulations and new products, with trials successfully completed for products entering the market in the next 12-18 months, supporting future growth and margin improvement.

    05

    Operational Efficiency and Market Trends

    Operational efficiency improved, with working capital days reducing from 225 to 200 days year-on-year. Staff costs increased by 20% due to new hiring for the subsidiary and R&D/marketing, but as a percentage of sales, it was lower than last year. The global agrochemical market is expected to grow in 2025, driven by increasing global population, climate change pressures, and the need for sustainable food production, with a focus on integrated pest management and advanced technologies like AI and machine learning.

    This is an AI-generated summary of a publicly available earnings call transcript. It is for informational purposes only and does not constitute investment advice, a recommendation, or an endorsement. inve.money is not a SEBI-registered investment advisor. Please consult a qualified financial advisor before making any investment decisions.